This Sunday November 15 Moffitt Cancer Center’s Dr Peter Forsyth, Dr Brian Czerniecki, and Dr Pawel Kalinski are presenting their award-winning Phase I results at the Society for Neuro-Oncology’s Annual meeting. Let’s discuss this cancer indication, why current treatments fail, and why this breakthrough matters enormously for both patients, Northwest Biotherapeutics, and Big Pharma.
1. What is this cancer?
Leptomeningeal disease (LMD) occurs when breast cancer cells spread into the cerebrospinal fluid (CSF), the liquid surrounding the brain and spinal cord, and the thin protective membranes lining them. It frequently strikes younger women with aggressive subtypes such as HER2+ or triple-negative breast cancer (TNBC).
2. Why do standard treatments fail?
Most intravenous chemotherapy and targeted antibody drugs cannot cross the blood-brain barrier into the spinal fluid in high enough concentrations to clear tumour cells hiding there. Spinal fluid naturally lacks trained killer T cells, and checkpoint inhibitors fail on their own because there are no properly instructed immune cells in the CSF for them to activate. Once breast cancer reaches the spinal fluid, patients deteriorate rapidly, suffering severe headaches, nerve damage, and loss of mobility or vision, with historical median survival typically lasting just 2 to 6 months.
3. Why is this a major breakthrough for patients?
Rather than poisoning the body with toxic drugs, Moffitt’s team took each patient’s own immune cells, trained them outside the body into Type-1 polarised dendritic cells (cDC1s), and infused them directly into the spinal fluid.
The data is quite impressive:
16.24-month median overall survival across 15 heavily pre-treated, post-radiation patients (10 HER2+, 5 TNBC), so roughly three to four times longer than historical outcomes, with manageable side effects (mainly temporary headaches as the immune response kicked in for the patient.
In every single patient, immune cell counts in the spinal fluid surged (from a median of 4 to 179 cells, reaching up to 2,550), driven by spikes in natural immune messengers (IFN-γ and IL-12) that reversed T-cell exhaustion.
4. Why is this critical for shareholders?
In 2020, Gilead Sciences paid $21 billion to buy Immunomedics for a breast cancer drug called Trodelvy. Then Daiichi Sankyo and AstraZeneca’s Enhertu came along and beat Trodelvy as the gold-standard targeted chemo drug in breast cancer achieving 10.4 to 13.3 months median survival in patients whose breast cancer spread into the spinal fluid (leptomeningeal disease).
This data (where patients did not even receive the full recommended dose as it was a Phase I safety trial), if continues into Phase II and III, beats Enhertu (which contains an FDA Black Box warning).
IP licensed by Northwest Biotherapeutics beat Enhertu in a dose-restricted Phase I trial with more than double DEBBRAH’s sample size.
Enhertu posted 13.3 months median OS in LMD (DEBBRAH) with an FDA Black Box warning.
Co-author Dr Pawel Kalinski is the pioneer behind αDC1 (alpha-type-1 polarised dendritic cell) biology. He co-invented the joint Kalinski–Czerniecki αDC1 patent filing (US 2024/0299544) and invented the licensed University of Pittsburgh ST-αDC1 patent (US 12,059,434), which are part of the exact dendritic cell portfolio Northwest Biotherapeutics exclusively in-licensed from Roswell Park and UPitt for commercial development.
Big Pharma’s checkpoint inhibitors fail in “cold” tumours because releasing the brakes on T cells achieves nothing if dendritic cells have not told them what to do in the patient.
Moffitt’s Phase II trial now pairs these intrathecal dendritic cells directly with nivolumab or trastuzumab proving that ex vivo DC vaccines are the essential foundation that makes other cancer drugs work.
Academic centres can produce small batches for local trials, but commercialising personalised dendritic cell therapies at scale requires automated, closed-system manufacturing which is precisely what Northwest Biotherapeutics has built with its EDEN (Flaskworks) platform and Sawston facility.
They also hired the top DC manufacturing expert from Roswell Park obviously to support future trials and the commercialization of Northwest Biotherapeutics entire immunotherapy pipeline.
Yet again it’s proven that Ex vivo DC instruction works while Big Pharma are clearly watching.
For this reason I must reiterate that Northwest Biotherapeutics have significant value upon MHRA approval of DCVax-L.
Sources:
https://virtual.oxfordabstracts.com/event/76734/submission/832
https://clinicaltrials.gov/study/NCT05809752
https://clinicaltrials.gov/study/NCT04348747
https://patents.justia.com/patent/20240299544
Disclosure: I hold shares of NWBO. I am not a clinician. I do not have a PhD in immunology, oncology, or structural biology. This is my opinion, not investment advice.


